Apr 23 |
Takeda Pharmaceutical: A Long-Term Cash Cow
|
Apr 23 |
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
|
Apr 22 |
Pharmas form joint venture to jumpstart Japanese drug research
|
Apr 22 |
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
|
Apr 19 |
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
|
Apr 18 |
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
|
Apr 8 |
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
|
Apr 5 |
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
Apr 5 |
Ovid Therapeutics gains on bullish view at Wedbush
|
Mar 27 |
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
|